Organovo Holdings, Inc. is a clinical-stage biotechnology company. Co. is focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues, as well as preclinical data. Its segments include research and development (R&D) and Mosaic Cell Sciences (Mosaic). It is also focused on building high fidelity, 3D tissues that recapitulate key aspects of human disease. It uses its proprietary technology to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease. We show 56 historical shares outstanding datapoints in our coverage of ONVO's shares outstanding history.
Understanding the changing numbers of ONVO shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like ONVO versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching ONVO by allowing them to research ONVO shares outstanding history
as well as any other stock in our coverage universe. |
Free ONVO Email Alerts:
Video: Shares Outstanding Importance
